Table 1.
Summary of subject demographic and baseline characteristics
| Treatment group | Retosiban | Placebo |
|---|---|---|
| Number treated | 30 | 34 |
| Age (years) mean (range) | 25.2 (18–39) | 27.8 (19–41) |
| BMI (kg m–2) mean (SD) | 25.8 (4.4) | 26.9 (4.3) |
| Race, n (%) | ||
| African American | 4 (13) | 2 (6) |
| American Indian or Alaskan Native | 1 (3) | 2 (6) |
| Asian | 2 (7) | 6 (18) |
| White – Arabic/North African | 1 (3) | 0 |
| White – White/Caucasian/European | 22 (73) | 24 (71) |
| Ethnicity, n (%) | ||
| Hispanic or Latino | 10 (33) | 12 (35) |
| Non-Hispanic or Latino | 20 (67) | 22 (65) |
| Gestational age, n (%) | ||
| 306/7–326/7 | 9 (30) | 15 (44) |
| 330/7–356/7 | 21 (70) | 19 (56) |
| Cervical dilatation, median cm | 2 | 2 |
| Contraction frequency, mean (SD) | 12.5 (7.5) | 12.9 (6.0) |
| Prior tocolytic, n (%) | 6 (20) | 10 (29) |
BMI, body mass index.